[go: up one dir, main page]

NO313864B1 - Vaksineadjuvans - Google Patents

Vaksineadjuvans Download PDF

Info

Publication number
NO313864B1
NO313864B1 NO19943920A NO943920A NO313864B1 NO 313864 B1 NO313864 B1 NO 313864B1 NO 19943920 A NO19943920 A NO 19943920A NO 943920 A NO943920 A NO 943920A NO 313864 B1 NO313864 B1 NO 313864B1
Authority
NO
Norway
Prior art keywords
immunogen
imidazo
quinolin
group
amine
Prior art date
Application number
NO19943920A
Other languages
English (en)
Norwegian (no)
Other versions
NO943920L (no
NO943920D0 (no
Inventor
Richard Miller
Mark Tomai
David Bernstein
Christopher Harrison
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Publication of NO943920L publication Critical patent/NO943920L/no
Publication of NO943920D0 publication Critical patent/NO943920D0/no
Publication of NO313864B1 publication Critical patent/NO313864B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19943920A 1992-04-16 1994-10-14 Vaksineadjuvans NO313864B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86938692A 1992-04-16 1992-04-16
PCT/US1993/003295 WO1993020847A1 (en) 1992-04-16 1993-04-08 Vaccine adjuvant

Publications (3)

Publication Number Publication Date
NO943920L NO943920L (no) 1994-10-14
NO943920D0 NO943920D0 (no) 1994-10-14
NO313864B1 true NO313864B1 (no) 2002-12-16

Family

ID=25353454

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19943920A NO313864B1 (no) 1992-04-16 1994-10-14 Vaksineadjuvans

Country Status (18)

Country Link
US (1) US6083505A (ja)
EP (1) EP0636031B1 (ja)
JP (2) JP3732506B2 (ja)
KR (1) KR100263804B1 (ja)
AT (1) ATE142110T1 (ja)
AU (1) AU674313B2 (ja)
CA (1) CA2118239C (ja)
DE (1) DE69304521T2 (ja)
DK (1) DK0636031T3 (ja)
ES (1) ES2092306T3 (ja)
HK (1) HK1007962A1 (ja)
HU (2) HU217209B (ja)
IL (1) IL105325A (ja)
MX (1) MX9302199A (ja)
NO (1) NO313864B1 (ja)
NZ (2) NZ252020A (ja)
WO (1) WO1993020847A1 (ja)
ZA (1) ZA932627B (ja)

Families Citing this family (226)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
ES2290969T3 (es) 1996-10-25 2008-02-16 Minnesota Mining And Manufacturing Company Compuestos modificadores de la respuesta inmune para el tratamiento de enfermedades mediadas por th2 y relacionadas.
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
CA2330610A1 (en) * 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) * 1999-12-28 2003-08-11 株式会社デンソー アクセル装置
US6894060B2 (en) * 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
GB0023008D0 (en) * 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
JP2005500510A (ja) * 2000-12-08 2005-01-06 スリーエム イノベイティブ プロパティズ カンパニー インターフェロンαを選択的に誘導する化合物を同定するための選別法
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
AU2006216669A1 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
WO2003020889A2 (en) * 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
EP1478371A4 (en) * 2001-10-12 2007-11-07 Univ Iowa Res Found METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
AU2002343728A1 (en) * 2001-11-16 2003-06-10 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor pathways
CN100473384C (zh) * 2001-11-29 2009-04-01 3M创新有限公司 包括免疫反应改性剂的药物制剂
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
MXPA04008023A (es) * 2002-02-22 2004-11-26 3M Innovative Properties Co Metodo para reducir y tratar inmunosupresion inducida por uvb.
GB0206461D0 (en) * 2002-03-19 2002-05-01 Glaxo Group Ltd Improvements in vaccination
US20050266024A1 (en) * 2002-03-19 2005-12-01 Powdermed Limited Adjuvant
US20030185835A1 (en) * 2002-03-19 2003-10-02 Braun Ralph P. Adjuvant for vaccines
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
WO2003080114A2 (en) * 2002-03-19 2003-10-02 Powdermed Limited Imidazoquinoline adjuvants for vaccines
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
MXPA04012199A (es) 2002-06-07 2005-02-25 3M Innovative Properties Co Imidazopiridinas sustituidas con eter.
JP4860923B2 (ja) 2002-08-15 2012-01-25 スリーエム イノベイティブ プロパティズ カンパニー 免疫刺激性組成物、および免疫応答の刺激方法
JP2006503068A (ja) * 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー １ｈ−イミダゾダイマー
WO2004053057A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
WO2004053452A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
NZ540826A (en) 2002-12-20 2008-07-31 3M Innovative Properties Co Aryl / hetaryl substituted imidazoquinolines
WO2004060319A2 (en) * 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
WO2004071459A2 (en) * 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
JP2006519020A (ja) * 2003-02-27 2006-08-24 スリーエム イノベイティブ プロパティズ カンパニー Ｔｌｒ介在生物活性の選択的調節
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
WO2004080398A2 (en) * 2003-03-07 2004-09-23 3M Innovative Properties Company 1-amino 1h-imidazoquinolines
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
US7179253B2 (en) 2003-03-13 2007-02-20 3M Innovative Properties Company Method of tattoo removal
US7699057B2 (en) * 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
KR20050109562A (ko) * 2003-03-13 2005-11-21 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피부의 질을 개선시키는 방법
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2004108072A2 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
US6943255B2 (en) * 2003-06-06 2005-09-13 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
AR044466A1 (es) * 2003-06-06 2005-09-14 3M Innovative Properties Co Proceso para la preparacion de imidazo [4,5-c] piridin-4-aminas
JP2007500713A (ja) * 2003-07-31 2007-01-18 スリーエム イノベイティブ プロパティズ カンパニー トリアジンを含む生理活性組成物
JP2007501252A (ja) * 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調整剤を含有する製剤
AR045260A1 (es) 2003-08-12 2005-10-19 3M Innovative Properties Co Compuestos que contienen imidazo-oxima sustituidos
US7799800B2 (en) * 2003-08-14 2010-09-21 3M Innovative Properties Company Lipid-modified immune response modifiers
JP2007503268A (ja) * 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾化合物の送達
JP2007504145A (ja) * 2003-08-25 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 免疫刺激性の組み合わせおよび治療
RU2006105101A (ru) 2003-08-27 2007-10-10 3М Инновейтив Пропертиз Компани (US) Арилокси и арилалкиленокси замещенные имидазохинолины
AU2004268665A1 (en) * 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
US20050054665A1 (en) * 2003-09-05 2005-03-10 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
EP1664342A4 (en) * 2003-09-17 2007-12-26 3M Innovative Properties Co SELECTIVE MODULATION OF TLR GENE EXPRESSION
KR101494056B1 (ko) 2003-10-03 2015-02-16 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
BRPI0414856A (pt) 2003-10-03 2006-11-21 3M Innovative Properties Co imidazoquinolinas alcóxi-substituìdas
US20050096259A1 (en) * 2003-10-31 2005-05-05 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
JP2007511535A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー ヒドロキシルアミン置換イミダゾ環化合物
AU2004291101A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
WO2005051324A2 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
EP1687307B1 (en) 2003-11-25 2016-01-06 3M Innovative Properties Company Substituted imidazo ring systems and methods
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
EP1689361A4 (en) * 2003-12-02 2009-06-17 3M Innovative Properties Co THERAPEUTIC COMBINATIONS AND PROCESSES WITH IRM COMPOUNDS
CA2549216A1 (en) * 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
JP2007530450A (ja) * 2003-12-29 2007-11-01 スリーエム イノベイティブ プロパティズ カンパニー ピペラジン、［１，４］ジアゼパン、［１，４］ジアゾカン、および［１，５］ジアゾカン縮合イミダゾ環化合物
EP1701955A1 (en) 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
WO2005067500A2 (en) * 2003-12-30 2005-07-28 3M Innovative Properties Company Enhancement of immune responses
CA2551399A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
US20070167479A1 (en) * 2004-03-15 2007-07-19 Busch Terri F Immune response modifier formulations and methods
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005110013A2 (en) * 2004-04-09 2005-11-24 3M Innovative Properties Company Methods, compositions, and preparations for delivery of immune response modifiers
CN101426524A (zh) * 2004-04-28 2009-05-06 3M创新有限公司 用于粘膜接种疫苗的组合物和方法
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
CA2571360C (en) * 2004-06-18 2014-11-25 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines useful in inducing cytokine biosynthesis in animals
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
EP1786450A4 (en) * 2004-08-27 2009-11-11 3M Innovative Properties Co HIV IMMUNOSTIMATORY COMPOSITIONS
US7579359B2 (en) * 2004-09-02 2009-08-25 3M Innovative Properties Company 1-alkoxy 1H-imidazo ring systems and methods
CA2578975A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
WO2006029223A2 (en) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
US20070243215A1 (en) * 2004-10-08 2007-10-18 Miller Richard L Adjuvant for Dna Vaccines
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
EP2394650A1 (en) * 2004-12-30 2011-12-14 3M Innovative Properties Co. Use of resiquimod for the treatment of cutaneous metastases
US20080119508A1 (en) * 2004-12-30 2008-05-22 3M Innovative Properties Company Multi-Route Administration Of Immune Response Modifier Compounds
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
NZ556399A (en) * 2004-12-30 2009-03-31 Takeda Pharmaceutical 1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine methanesulfonate
ES2392648T3 (es) 2004-12-30 2012-12-12 3M Innovative Properties Company Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
ES2475728T3 (es) 2005-02-09 2014-07-11 3M Innovative Properties Company Tiazoloquinolinas y tiazolonaftiridinas sustituidas con alcoxi
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
CA2597446A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
HUE030881T2 (en) 2005-02-18 2017-06-28 Glaxosmithkline Biologicals Sa Meningitis / sepsis-associated escherichia coli proteins and nucleic acids
JP2008531567A (ja) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン化合物および方法
WO2006091647A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
AU2006223634A1 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
WO2006091568A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
CN101175493A (zh) 2005-03-14 2008-05-07 3M创新有限公司 治疗光化性角化病的方法
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
AU2006232377A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
AU2006241166A1 (en) * 2005-04-25 2006-11-02 3M Innovative Properties Company Immunostimulatory compositions
CA2615626A1 (en) 2005-07-18 2007-01-25 Novartis Ag Small animal model for hcv replication
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
US8476292B2 (en) 2005-09-09 2013-07-02 3M Innovative Properties Company Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
WO2007052055A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP5247458B2 (ja) 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー ヒドロキシ及びアルコキシ置換１ｈ−イミダゾキノリン及び方法
EP2377552A3 (en) 2005-11-04 2013-05-15 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines with reduced amount of emulsion adjuvant
JP2009514839A (ja) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
JP2009514841A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 粒子状アジュバントと免疫増強物質との組合せを含むインフルエンザワクチン
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
DK1976559T6 (da) 2006-01-27 2020-04-06 Seqirus Uk Ltd Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
CA2647100A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
ES2376492T3 (es) * 2006-03-23 2012-03-14 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores.
ES2388556T3 (es) * 2006-03-23 2012-10-16 Novartis Ag Compuestos inmunopotenciadores
US20100068223A1 (en) 2006-03-24 2010-03-18 Hanno Scheffczik Storage of Influenza Vaccines Without Refrigeration
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US20100285062A1 (en) 2006-03-31 2010-11-11 Novartis Ag Combined mucosal and parenteral immunization against hiv
DE102006015585A1 (de) * 2006-04-04 2007-10-18 Mahle International Gmbh Kolben für einen Verbrennungsmotor
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
WO2007121491A1 (en) * 2006-04-25 2007-11-01 Intercell Ag Hcv vaccinations
CA2652280C (en) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
WO2007142755A2 (en) 2006-05-31 2007-12-13 The Regents Of The University Of California Purine analogs
EP2054431B1 (en) 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
JP5564249B2 (ja) 2006-06-23 2014-07-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌に関与するポリヌクレオチド配列およびポリペプチド配列
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008019142A2 (en) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
AU2007285484B2 (en) 2006-08-16 2013-05-02 Novartis Ag Immunogens from uropathogenic Escherichia coli
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
CA2671629C (en) 2006-12-06 2017-08-15 Novartis Ag Vaccines including antigen from four strains of influenza virus
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
SI2510946T1 (sl) 2007-02-07 2015-12-31 The Regents Of The University Of California Konjugati sintetičnih agonistov TLR in njihove uporabe
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124632A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
CA2685308A1 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2620157A3 (en) 2007-10-12 2013-10-16 Massachusetts Institute of Technology Vaccine nanotechnology
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2259788A4 (en) * 2008-02-07 2011-03-16 Univ California TREATMENT OF BLADDER DISEASES WITH A TLR7 ACTIVATOR
EP3459563A1 (en) 2008-03-18 2019-03-27 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
EP3130674B1 (en) 2008-11-03 2020-07-08 ADC Therapeutics SA Antibodies that specifically block the biological activity of a tumor antigen
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
BRPI1008383A2 (pt) 2009-02-11 2016-02-23 Univ California composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
CA2754618A1 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
MX363222B (es) 2009-04-14 2019-03-15 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.
EP2424565A1 (en) 2009-04-27 2012-03-07 Novartis AG Adjuvanted vaccines for protecting against influenza
EP3988115A3 (en) 2009-07-15 2022-08-17 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
EP2464658B1 (en) 2009-07-16 2014-10-01 Novartis AG Detoxified escherichia coli immunogens
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
MX352324B (es) 2010-05-26 2017-11-17 Selecta Biosciences Inc Star Vacunas multivalentes de nanovehiculos sinteticos.
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
BR112013003772A2 (pt) 2010-08-17 2016-08-02 3M Innovative Properties Co composições de compostos modificadores de resposta imunológica lipidadas, formulações e métodos
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
US10342862B2 (en) 2011-01-26 2019-07-09 Glaxosmithkline Biologicals, Sa RSV immunization regimen
DK3173427T3 (da) 2011-03-31 2019-08-05 Adc Therapeutics Sa Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf
LT2707385T (lt) 2011-05-13 2017-12-11 Glaxosmithkline Biologicals Sa Iš anksto sulieti rsv f antigenai
EP2718292B1 (en) 2011-06-03 2018-03-14 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
JP6460789B2 (ja) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
WO2013019648A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
EA035493B1 (ru) 2011-12-22 2020-06-25 Янссен Байофарма, Инк. Замещенные нуклеозиды, нуклеотиды и их аналоги
ES2731665T3 (es) 2012-01-09 2019-11-18 Adc Therapeutics Sa Agentes para tratar cáncer de mama triple negativo
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MX376235B (es) 2012-05-04 2025-03-07 Pfizer Inc Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna.
US10071051B2 (en) 2013-02-05 2018-09-11 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
CA2840954A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
RU2014102941A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для введения через слизистую оболочку
CN103961700A (zh) 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
CN103961696A (zh) 2013-02-05 2014-08-06 日东电工株式会社 经皮给予用疫苗组合物
CN103961307B (zh) 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
JP6512569B2 (ja) 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチンテープ剤
EP2762154A3 (en) 2013-02-05 2015-01-21 Nitto Denko Corporation Vaccine composition for transdermal administration
CN103961701B (zh) 2013-02-05 2018-09-14 日东电工株式会社 疫苗组合物
CN103961702B (zh) 2013-02-05 2019-04-09 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US10328140B2 (en) 2014-03-26 2019-06-25 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
WO2017046675A1 (en) 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
JP7197244B2 (ja) 2017-12-20 2022-12-27 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤として使用するための分岐鎖連結基を有するアミド置換イミダゾ［４，５－ｃ］キノリン化合物
WO2021226088A1 (en) * 2020-05-05 2021-11-11 Virovax Llc Vaccine adjuvants

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1271477A (en) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4716168A (en) * 1985-01-08 1987-12-29 Norwich Eaton Pharmaceuticals, Inc. Imidazo(4,5-f)quinolines useful as immunomodulating agents
US4689224A (en) * 1985-10-07 1987-08-25 Neogen Corporation Method for administering vaccines containing equine leukokines and compositions therefor
US4619827A (en) * 1985-10-07 1986-10-28 Neogen Corporation Method for administering equine vaccines and compositions therefor
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
ATE60999T1 (de) * 1986-12-19 1991-03-15 Duphar Int Res Dimethyldioctadecylammoniumbromid enthaltende stabilisierte adjuvanssuspension.
ZA881694B (en) * 1987-03-17 1988-09-06 Akzo N.V. Adjuvant mixture
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
IL92537A (en) * 1988-12-15 1994-04-12 Riker Laboratories Inc Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
ES2094141T3 (es) * 1989-02-27 1997-01-16 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolin-4-aminas como antivirales.
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) * 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US5015476A (en) * 1989-08-11 1991-05-14 Paravax, Inc. Immunization implant and method
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules

Also Published As

Publication number Publication date
ES2092306T3 (es) 1996-11-16
HU211298A9 (en) 1995-11-28
IL105325A0 (en) 1993-08-18
NZ252020A (en) 1995-12-21
WO1993020847A1 (en) 1993-10-28
HUT69993A (en) 1995-09-28
EP0636031A1 (en) 1995-02-01
HK1007962A1 (en) 1999-04-30
KR100263804B1 (ko) 2000-08-16
NO943920L (no) 1994-10-14
IL105325A (en) 1996-11-14
ATE142110T1 (de) 1996-09-15
JP2004043496A (ja) 2004-02-12
JP3732506B2 (ja) 2006-01-05
AU674313B2 (en) 1996-12-19
AU4048093A (en) 1993-11-18
MX9302199A (es) 1994-08-31
EP0636031B1 (en) 1996-09-04
DE69304521D1 (de) 1996-10-10
JPH07505883A (ja) 1995-06-29
NO943920D0 (no) 1994-10-14
ZA932627B (en) 1994-10-14
DE69304521T2 (de) 1997-02-20
NZ280098A (en) 1998-06-26
CA2118239C (en) 2009-04-07
HU217209B (hu) 1999-12-28
DK0636031T3 (ja) 1997-02-24
CA2118239A1 (en) 1993-10-28
HU9402978D0 (en) 1995-02-28
US6083505A (en) 2000-07-04

Similar Documents

Publication Publication Date Title
NO313864B1 (no) Vaksineadjuvans
BRPI1011072B1 (pt) Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo
UA117732C2 (uk) Парентеральна норовірусна вакцина
Boulter Humoral and cellular aspects of the response to infection: Protection against poxviruses
Cong et al. Multi-epitope DNA vaccine linked to the A2/B subunit of cholera toxin protect mice against Toxoplasma gondii
US6936263B2 (en) Th1 inducing natural adjuvant for heterologous antigens
Playfair et al. Reactivity and crossreactivity of mouse helper T cells to malaria parasites
Cook et al. Immunogenicity of soluble and particulate antigens from Leishmania donovani: effect of glucan as an adjuvant
EP1768696B1 (en) Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
Blancou et al. Kinetics of different specific immunological parameters after rabies vaccination in mice
AU711915B2 (en) Plasmid vaccine against pseudorabies virus
Domer In vivo and in virto cellular responses to cytoplasmic and cell wall antigens of Histoplasma capsulatum in artificially immunized or infected guinea pigs
CN107164252B (zh) 一种rhdv的亚单位疫苗
Fukuda et al. Acquired antibody against pseudotuberculosis in yellowtail
KR20220110785A (ko) 애비박테리움 파라갈리나룸 및 조류 뇌척수염 바이러스 및 계두 바이러스에 대한 삼중 백신
AU683030B2 (en) Immunization against (neisseria gonorrhoeae) and (neisseria meningitidis)
Nathanson et al. Cyclophosphamide-induced immunosuppression demonstrated in Pasteurella multocida-vaccinated chickens
Mitsui et al. Experiments in human volunteers with adenovirus type 8
Lazàry et al. Immune response to haemophilus parahaemolyticus (HP) infection in the pig I. In vitro tests to detect sensitized cells in the blood of infected and vaccinated animals
RU2021816C1 (ru) Способ получения вакцины против холеры
CA2141475C (en) Type 1 and type p fimbriae-adhesins isolated from novel e. coli strains, process for their preparation and uses thereof
WO2006116053A1 (en) Immunomodulator compounds as vaccine enhancers
Burland Measles vaccination by the intradermal route
Senyk et al. Cell-mediated immune responses to chlamydial antigens in guinea pigs injected with inactivated chlamydiae
Van Oirschot et al. Early protection after vaccination against Aujeszky’s disease

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees